Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TNF | P01375 | 2/20 | 0.37 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.36 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.36 |
| ▸ | SSTR5 | P35346 | 7/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SSTR2 | P30874 | 3/20 | 0.34 |
| ▸ | SSTR3 | P32745 | 3/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14473900 | 1.00 | LMNA (0.38) | LMNAKMT2ATNFLGALS8LGALS3 | |
| SCHEMBL16234426 | 0.91 | LMNA (0.40) | LMNAKMT2ATNFLGALS8LGALS3 | |
| SCHEMBL14474347 | 0.84 | PAX8 (0.41) | LMNAKMT2ATSHR | |
| SCHEMBL16234429 | 0.84 | PAX8 (0.41) | LMNAKMT2ATSHR | |
| SCHEMBL16232445 | 0.80 | LMNA (0.44) | LMNAKMT2ALGALS8LGALS3TSHR | |
| SCHEMBL15581555 | 0.76 | LMNA (0.64) | LMNAKMT2ATSHRMAPK1 | |
| SCHEMBL16690984 | 0.76 | LMNA (0.64) | LMNAKMT2ATSHRMAPK1 | |
| SCHEMBL14479098 | 0.73 | AGTR1 (0.39) | KMT2ALGALS8LGALS3 | |
| SCHEMBL14479046 | 0.73 | AGTR1 (0.39) | KMT2ALGALS8LGALS3 | |
| SCHEMBL14478847 | 0.73 | AGTR1 (0.39) | KMT2ALGALS8LGALS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140336369-A1 | PROCESS FOR PREPARING HEPARINOIDS AND INTERMEDIATES USEFUL IN THE SYNTHESIS THEREOF | APICORE US LLC (US) | 2014-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336369-A1 | PROCESS FOR PREPARING HEPARINOIDS AND INTERMEDIATES USEFUL IN THE SYNTHESIS THEREOF | HPSE, STS, F11 | LMNA 900/4885KMT2A 3385/4885TNF 1992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.